TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00165178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
Study: NCT00773201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol 80 mg
Description: healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
Study: NCT00706901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 1 GMI
Description: Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller \& Rollnick 2013) and based on a manualized protocol (Martino \& Santa Ana 2013; Santa Ana \& Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 2 IHMD
Description: Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 3 TCC
Description: TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 3 TCC
Description: TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3 TCC
Description: TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
Study: NCT00165178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
Study: NCT01283659

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Imaging
Study: NCT05587075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Filiform needle
Description: A needle treatment: guide patients take lying or sitting, keep relaxed, select Jingjiaji Point, Fengchi Point, Jianjing Point, Tianzhu Point, Houxi point, Hegu Point, Waiguan Point, preoperative, marker points, conventional disinfection, application specification of 0.35mmx50mm disposable sterile acupuncture needle, in the marker quick needle subcutaneous, slow needle to feel acid swelling feeling, keep needle 30min, once a day, last 5d for 1 course, a total of 4 courses of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long round needle
Description: Long round needle treatment: mark tendon lesions, take 3-5 tendon lesion points for needle point, after injection of 0.5% lidocaine 1mL, local anesthesia, to hold long round needle, slowly hierarchical detection to tendon lesion points, patients feel acid, hemp, swelling feeling is appropriate, to close method line knot treatment: straight to tendon lesions point surface, scraping, to remove the surface adhesion. Do not cross the superficial surface of the clavicle, sternocleidomastoid muscle deep surface, gentle action. After the needle was released, the pinhole was covered with a disposable dressing, bandaged for 2d, once a week, once for 1 course, and for a total of 4 courses of treatment.
Study: NCT03478813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voiding school
Description: Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
Study: NCT00241059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Study: NCT02046655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Study: NCT00681447

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Interlaminar Epidural
Description: 1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone
Study: NCT00165178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
Study: NCT00681447

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Interlaminar Epidural
Description: 1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Interlaminar Epidural injection
Description: 1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Interlaminar Epidural injection
Description: 1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone
Study: NCT00165178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase
Description: Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate/Hydrocortisone
Description: Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
Study: NCT03010228

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA15 without Alum
Description: I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
Study: NCT00165178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate/Hydrocortisone
Description: Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate/Hydrocortisone
Description: Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate/Hydrocortisone
Description: Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
Study: NCT06200753

Intervention type: PROCEDURE
Intervention: Mechanical Thrombectomy
Description: Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage.~Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage.~Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury.

Intervention type: PROCEDURE
Intervention: Mechanical Thrombectomy
Description: Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage.~Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage.~Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury.
Study: NCT00502554

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: photopheresis
Description: 2-day cycles of photopheresis every 3 weeks for 3 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photopheresis
Description: 2-day cycles of photopheresis every 3 weeks for 3 months
Study: NCT05078372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine and midazolam intraarticular administration
Description: Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure, and intraarticular administration of those drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine and midazolam epidural administration
Description: Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure
Study: NCT02906397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib 150mg by mouth twice a day
Description: on days 1-14 of 28 day cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 18GY delivered in one fraction between C1D15 and C1D28
Study: NCT00699608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1755165; placebo; zopiclone
Description: Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
Study: NCT01299181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80mg once daily orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: 80mg once daily orally
Study: NCT01929382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon gamma 1b
Description: Standard therapy vs dose titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon gamma 1b
Description: Standard therapy vs dose titration
Study: NCT04080102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Exercise
Study: NCT02652975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laboratory blood samples
Description: Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laboratory blood samples
Description: Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen.
Study: NCT05992792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App message
Description: Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS message
Description: Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
Study: NCT04080102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acid
Description: Oral ingestion of a powdered dietary supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training and essential amino acid supplement
Description: Exercise and dietary supplement
Study: NCT03590314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group - robot assisted arm training (Armotion®)
Description: Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:~* Collect the coins~* Drive the car~* Wash the dishes~* Burst the balloons~For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group - conventional treatment
Description: Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
Study: NCT01388907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate solution
Description: Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevadh film
Description: Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
Study: NCT01381068

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: End tidal CO2 monitor
Description: The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
Study: NCT03502473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power device
Description: UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~* The Main console~* Transducer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power device
Description: UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~* The Main console~* Transducer
Study: NCT01910402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/abacavir/lamivudine FDC
Description: Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Atazanavir capsule 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir tablet 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/emtricitabine FDC
Description: Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
Study: NCT03470480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Repetitive transcranial magnetic stimulation
Description: A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Repetitive transcranial magnetic stimulation
Description: A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Methamphetamine visual cues
Description: Just before each rTMS session, participants will be shown methamphetamine-related pictures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Methamphetamine visual cues
Description: Just before each rTMS session, participants will be shown methamphetamine-related pictures

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral visual cues
Description: Just before each rTMS session, participants will be shown neutral pictures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral visual cues
Description: Just before each rTMS session, participants will be shown neutral pictures
Study: NCT03736941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with venous leg
Description: The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.